VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug

Viking Therapeutics (VKTX) announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation of its experimental obesity drug VK2735. Data from this study is expected in the second half of 2025.This study has enrolled around 280 adults who are either obese or overweight and have at least one weight-related co-morbid condition. These patients have been evenly randomized to one of the six dosing arms of t ...